Abstract Number: 0498 • ACR Convergence 2024
ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…Abstract Number: 0514 • ACR Convergence 2024
Efficacy, Safety and Mechanism of Butyrate in the Treatment of Rheumatoid Arthritis (RA)
Background/Purpose: This study aims to investigate the safety and efficacy of butyrate capsules in treating patients with rheumatoid arthritis (RA) and elucidate the underlying mechanisms.Methods:…Abstract Number: 0532 • ACR Convergence 2024
An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs
Background/Purpose: Despite significant therapeutic advancements in rheumatoid arthritis (RA), a substantial proportion of patients (20-40%) remain unresponsive to current treatments, including targeted synthetic DMARDs. A…Abstract Number: 0803 • ACR Convergence 2024
Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort
Background/Purpose: Adipokines are metabolic cytokines shown to be dysregulated in RA and prognostic of RA-related complications such as cardiovascular disease. Similarly, aberrations in adipokines have…Abstract Number: 0899 • ACR Convergence 2024
Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors…Abstract Number: 0949 • ACR Convergence 2024
CCN1 Is a Novel Therapeutic Target for Reducing Structural Damage in Rheumatoid Arthritis: Demonstration from 2 Preclinical Models
Background/Purpose: We have previously shown that the matricellular protein CCN1, characterized by angiogenic and immunomodulatory properties, is overexpressed in endothelial cells and synovial tissue of…Abstract Number: 1016 • ACR Convergence 2024
Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S
Background/Purpose: Long-term management of rheumatoid arthritis (RA) relies on disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic (tsDMARDs). About 40%…Abstract Number: 1077 • ACR Convergence 2024
Pragmatic Quantitative Rheumatologist 0–10 Visual Numeric Scale Estimates of Inflammation, Damage, and Patient Distress Have Face Validity and May Be as Informative as Formal 28 Joint Counts in Rheumatoid Arthritis
Background/Purpose: A 28 joint count of swelling (SJC), tenderness/pain on motion (TJC), and deformity/limited motion (DJC), is recommended to assess rheumatoid arthritis (RA) patient status.…Abstract Number: 1330 • ACR Convergence 2024
Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis
Background/Purpose: Alterations in gut microbiota (dysbiosis) may contribute to the development of rheumatoid arthritis (RA). Elevated fecal calprotectin (F-calprotectin), an established biomarker of gut inflammation, has…Abstract Number: 1346 • ACR Convergence 2024
Early Diagnosis of Rheumatoid Arthritis: Role of Joint Ultrasound Assessment
Background/Purpose: Early diagnosis of Rheumatoid Arthritis (RA) is essential to establish treatment to improve long-term disease outcomes. Musculoskeletal ultrasound (US) is able to detect subclinical…Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…Abstract Number: 1378 • ACR Convergence 2024
Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis
Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…Abstract Number: 1395 • ACR Convergence 2024
Effects of Butyrate Supplementation in Modulation of Gut Microbiome and Its Metabolites in New Onset Rheumatoid Arthritis
Background/Purpose: The gut microbiome and its metabolites are dysregulated in RA and other immune-mediated inflammatory diseases. However, the significance of this observation and its implications…Abstract Number: 1663 • ACR Convergence 2024
Notch—mediated Fibrogenic Activation Is a Spatial Determinant of RA Treatment Response
Background/Purpose: In RA, poor treatment response has been linked to a fibroid synovial tissue phenotype, characterized by lack of immune cell infiltration and an expansion…Abstract Number: 1745 • ACR Convergence 2024
Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis
Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher incidence of…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 188
- Next Page »